

GARDP's pipeline (May 2021)

DISCOVERY	DISEASE AREA	TRANSLATIONAL	DEVELOPMENT		REGULATORY	IMPLEMENTATION
		Pre-clinical / Early Clinical	Pediatric trials	Phase 3	Registration Status	Access Development
AMR Screening Consortium Eisai, Takeda & Daiichi S. Antibiotic potentiators Calibr / Scripps Natural Products HIPS	SERIOUS BACTERIAL INFECTIONS	Potential candidate A (NCE or repurposed)		Cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals**		Access strategy
CHILDREN'S ANTIBIOTICS	NEONATAL SEPSIS	IV Fosfomycin	Treatment regimens Public health strategic efficacy and safety trials		Approved in EU, with Neo & Paeds label	
		Flomoxef			Approved in Asia: Neo & Paeds data	
		Amikacin			Approved globally: Neo & Paeds data	
	PAEDIATRIC DEVELOPMENT	Polymyxin B*	Approved in USA, with limited Neo & Paeds label			
		Paediatric cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals				
		Potential candidate A (NCE or repurposed)				
SEXUALLY TRANSMITTED INFECTIONS			Zoliflodacin (NCE) Entasis Therapeutics Inc.	Access strategy Including manufacturing development		
	Potential candidate B (NCE)		Approved in USA / EU for CABP	Surveillance / Prevalence studies		

* Under review / on-hold

** Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Wellcome Trust in the United Kingdom

